Drug radiotherapy combinations: Review of previous failures and reasons for future optimism

Cancer Treatment Reviews

Volumn 41, Issue 2, 2015, Pages 105-113

  Higgins, Geoff S ^a,b   O'Cathail, Sean M ^b   Muschel, Ruth J ^a   McKenna, W Gillies ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Chemo radiotherapy; Drug radiotherapy combinations; Radiosensitisation; Tumour hypoxia

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; 2 NITROIMIDAZOLE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALKALINE PHOSPHATASE; AMIFOSTINE; ANGIOGENESIS INHIBITOR; ARABINOSIDE; ATR PROTEIN; BEVACIZUMAB; BIOLOGICAL MARKER; BUPARLISIB; CARBONATE DEHYDRATASE; CEDIRANIB; CETUXIMAB; EVEROLIMUS; EVOFOSFAMIDE; FLUORODEOXYGLUCOSE F 18; GEFITINIB; METFORMIN; MISONIDAZOLE; NELFINAVIR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIMORAZOLE; NITROIMIDAZOLE; NITROIMIDAZOLE DERIVATIVE; PANITUMUMAB; SELUMETINIB; TEMSIROLIMUS; TIRAPAZAMINE; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; RADIOSENSITIZING AGENT;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER RADIOTHERAPY; CAPILLARY DENSITY; CHEMORADIOTHERAPY; COLORECTAL CARCINOMA; DNA REPAIR; HEAD AND NECK CANCER; HUMAN; HYPOXIA; LUNG ADENOCARCINOMA; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; OPTIMISM; OROPHARYNX TUMOR; OVARY CANCER; OVERALL SURVIVAL; OXYGEN CONSUMPTION; PROTEIN EXPRESSION; QUALITY OF LIFE; RADIATION PROTECTION; RADIOSENSITIVITY; RADIOSENSITIZATION; RECTUM CANCER; RECURRENCE RISK; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ADJUVANT CHEMORADIOTHERAPY; ADVERSE EFFECTS; CELL HYPOXIA; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENETICS; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOPHYSIOLOGY; PROCEDURES; TREATMENT FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL HYPOXIA; CHEMORADIOTHERAPY; CHEMORADIOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DNA REPAIR; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

EID: 84921763721     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.12.012     Document Type: Review

References (82)

1. Bentzen S.M., Heeren G., Cottier B., Slotman B., Glimelius B., Lievens Y., et al. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol 2005, 75(3):355-365. Epub 2005/08/10.
2. Jaffray D.A. Image-guided radiotherapy: from current concept to future perspectives. Nat Rev Clin Oncol 2012, 9(12):688-699. Epub 2012/11/21.
3. Castedo M., Perfettini J.L., Roumier T., Andreau K., Medema R., Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004, 23(16):2825-2837. Epub 2004/04/13.
4. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004, 14(3):198-206. Epub 2004/07/16.
5. Auperin A., Le Pechoux C., Rolland E., Curran W.J., Furuse K., Fournel P., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(13):2181-2190. Epub 2010/03/31.
6. Green J.A., Kirwan J.M., Tierney J.F., Symonds P., Fresco L., Collingwood M., et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001, 358(9284):781-786. Epub 2001/09/21.
7. Pignon J.P., le Maitre A., Maillard E., Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92(1):4-14. Epub 2009/05/19.
8. Gerard J.P., Conroy T., Bonnetain F., Bouche O., Chapet O., Closon-Dejardin M.T., et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24(28):4620-4625. Epub 2006/09/30.
9. Bussink J., van der Kogel A.J., Kaanders J.H. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008, 9(3):288-296. Epub 2008/03/01.
10. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New Engl J Med 2006, 354(6):567-578. Epub 2006/02/10.
11. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman E, Weber R, et al., editors. A Randomized Phase III Trial (RTOG 0522) of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III-IV Head and Neck Squamous Cell Carcinomas (HNC). American Society of Clinical Oncology Annual Meeting; 2011; Chicago: J Clin Oncol.
12. Maier P, Wenz F, Herskind C. Radioprotection of normal tissue cells. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al.] 2014;190(8):745-752. Epub 2014/03/19.
13. Nicolatou-Galitis O., Sarri T., Bowen J., Di Palma M., Kouloulias V.E., Niscola P., et al. Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer 2013, 21(1):357-364. Epub 2012/10/12.
14. Urtasun R.C., Chapman J.D., Feldstein M.L., Band R.P., Rabin H.R., Wilson A.F., et al. Peripheral neuropathy related to misonidazole: incidence and pathology. Br J Cancer Suppl 1978, 3:271-275. Epub 1978/06/01.
15. Overgaard J., Hansen H.S., Andersen A.P., Hjelm-Hansen M., Jorgensen K., Sandberg E., et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 1989, 16(4):1065-1068. Epub 1989/04/01.
16. Overgaard J., Hansen H.S., Overgaard M., Bastholt L., Berthelsen A., Specht L., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998, 46(2):135-146. Epub 1998/03/24.
17. Toustrup K., Sorensen B.S., Lassen P., Wiuf C., Alsner J., Overgaard J. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 2012, 102(1):122-129. Epub 2011/10/15.
18. Rami M., Dubois L., Parvathaneni N.K., Alterio V., van Kuijk S.J., Monti S.M., et al. Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates. J Med Chem 2013, 56(21):8512-8520. Epub 2013/10/17.
19. Dubois L., Peeters S.G., van Kuijk S.J., Yaromina A., Lieuwes N.G., Saraya R., et al. Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs. Radiother Oncol 2013, 108(3):523-528. Epub 2013/07/16.
20. Reddy S.B., Williamson S.K. Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs 2009, 18(1):77-87.
21. Saggar J.K., Tannock I.F. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy. Int J Cancer 2014, 134(11):2726-2734. Epub 2013/12/18.
22. Liu Q., Sun J.D., Wang J., Ahluwalia D., Baker A.F., Cranmer L.D., et al. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol 2012, 69(6):1487-1498. Epub 2012/03/03.
23. Chawla S.P., Cranmer L.D., Van Tine B.A., Reed D.R., Okuno S.H., Butrynski J.E., et al. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol 2014, 32(29):3299-3306.
24. Peters L., Rischin D. Elusive goal of targeting tumor hypoxia for therapeutic gain. J Clin Oncol 2012, 30(15):1741-1743.
25. Lopci E., Grassi I., Chiti A., Nanni C., Cicoria G., Toschi L., et al. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am J Nucl Med Mol Imaging 2014, 4(4):365-384. Epub 2014/07/02.
26. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006;24(13):2098-2104. Epub 2006/05/02.
27. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007, 99(19):1441-1454.
28. Zips D., Zophel K., Abolmaali N., Perrin R., Abramyuk A., Haase R., et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol 2012, 105(1):21-28.
29. Zegers CM, van Elmpt W, Reymen B, Even AJ, Troost EG, Ollers MC, et al. In Vivo Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014. Epub 2014/10/16.
30. Koch C.J., Scheuermann J.S., Divgi C., Judy K.D., Kachur A.V., Freifelder R., et al. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging 2010, 37(11):2048-2059. Epub 2010/06/30.
31. Nagy J.A., Chang S.H., Dvorak A.M., Dvorak H.F. Why are tumour blood vessels abnormal and why is it important to know?. Br J Cancer 2009, 100(6):865-869. Epub 2009/02/26.
32. Gray L.H., Conger A.D., Ebert M., Hornsey S., Scott O.C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953, 26(312):638-648. Epub 1953/12/01.
33. Kleibeuker E.A., Griffioen A.W., Verheul H.M., Slotman B.J., Thijssen V.L. Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist Updat 2012, 15(3):173-182. Epub 2012/05/09.
34. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25(12):1539-1544. Epub 2007/04/20.
35. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011, 91(3):1071-1121. Epub 2011/07/12.
36. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New Engl J Med 2006, 355(24):2542-2550. Epub 2006/12/15.
37. Dings R.P., Loren M., Heun H., McNiel E., Griffioen A.W., Mayo K.H., et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007, 13(11):3395-3402. Epub 2007/06/05.
38. Chinot O.L., Wick W., Mason W., Henriksson R., Saran F., Nishikawa R., et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. New Engl J Med 2014, 370(8):709-722. Epub 2014/02/21.
39. Gilbert M.R., Dignam J.J., Armstrong T.S., Wefel J.S., Blumenthal D.T., Vogelbaum M.A., et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. New Engl J Med 2014, 370(8):699-708. Epub 2014/02/21.
40. Gupta A.K., Bakanauskas V.J., Cerniglia G.J., Cheng Y., Bernhard E.J., Muschel R.J., et al. The Ras radiation resistance pathway. Cancer Res 2001, 61(10):4278-4282. Epub 2001/05/19.
41. Fokas E., Yoshimura M., Prevo R., Higgins G., Hackl W., Maira S.M., et al. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiat Oncol 2012, 7:48. Epub 2012/03/29.
42. Albert J.M., Kim K.W., Cao C., Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 2006, 5(5):1183-1189. Epub 2006/05/30.
43. Gupta A.K., Cerniglia G.J., Mick R., McKenna W.G., Muschel R.J. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005, 65(18):8256-8265. Epub 2005/09/17.
44. Chung E.J., Brown A.P., Asano H., Mandler M., Burgan W.E., Carter D., et al. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res 2009, 15(9):3050-3057. Epub 2009/04/16.
45. Qayum N., Muschel R.J., Im J.H., Balathasan L., Koch C.J., Patel S., et al. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 2009, 69(15):6347-6354. Epub 2009/07/23.
46. Fokas E., Im J.H., Hill S., Yameen S., Stratford M., Beech J., et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 2012, 72(1):239-248. Epub 2011/11/24.
47. Rengan R., Mick R., Pryma D., Rosen M.A., Lin L.L., Maity A.M., et al. A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response. J Thorac Oncol 2012, 7(4):709-715. Epub 2012/03/20.
48. Buijsen J., Lammering G., Jansen R.L., Beets G.L., Wals J., Sosef M., et al. Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer. Radiother Oncol 2013, 107(2):184-188. Epub 2013/05/08.
49. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434(7035):917-921. Epub 2005/04/15.
50. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434(7035):913-917. Epub 2005/04/15.
51. Goodhead D.T. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int J Radiat Biol 1994, 65(1):7-17. Epub 1994/01/01.
52. Saleh-Gohari N., Bryant H.E., Schultz N., Parker K.M., Cassel T.N., Helleday T. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol 2005, 25(16):7158-7169. Epub 2005/08/02.
53. Powell C., Mikropoulos C., Kaye S.B., Nutting C.M., Bhide S.A., Newbold K., et al. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev 2010, 36(7):566-575. Epub 2010/04/23.
54. Colodner K.J., Montana R.A., Anthony D.C., Folkerth R.D., De Girolami U., Feany M.B. Proliferative potential of human astrocytes. J Neuropathol Exp Neurol 2005, 64(2):163-169. Epub 2005/03/09.
55. Ciccia A., Elledge S.J. The DNA damage response: making it safe to play with knives. Mol Cell 2010, 40(2):179-204. Epub 2010/10/23.
56. Smith J., Tho L.M., Xu N., Gillespie D.A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010, 108:73-112. Epub 2010/11/03.
57. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455(7216):1069-1075. Epub 2008/10/25.
58. Charrier J.D., Durrant S.J., Golec J.M., Kay D.P., Knegtel R.M., MacCormick S., et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J Med Chem 2011, 54(7):2320-2330. Epub 2011/03/19.
59. Foote K.M., Blades K., Cronin A., Fillery S., Guichard S.S., Hassall L., et al. Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-y l}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J Med Chem 2013, 56(5):2125-2138. Epub 2013/02/12.
60. Fokas E., Prevo R., Pollard J.R., Reaper P.M., Charlton P.A., Cornelissen B., et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis 2012, 3:e441. Epub 2012/12/12.
61. Reaper P.M., Griffiths M.R., Long J.M., Charrier J.D., Maccormick S., Charlton P.A., et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 2011, 7(7):428-430. Epub 2011/04/15.
62. Prevo R., Fokas E., Reaper P.M., Charlton P.A., Pollard J.R., McKenna W.G., et al. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther 2012, 13(11):1072-1081. Epub 2012/07/25.
63. Pires I.M., Olcina M.M., Anbalagan S., Pollard J.R., Reaper P.M., Charlton P.A., et al. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. Br J Cancer 2012, 107(2):291-299. Epub 2012/06/21.
64. Secomb T.W., Hsu R., Ong E.T., Gross J.F., Dewhirst M.W. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol 1995, 34(3):313-316. Epub 1995/01/01.
65. Dowling R.J., Goodwin P.J., Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011, 9:33. Epub 2011/04/08.
66. Skinner H.D., McCurdy M.R., Echeverria A.E., Lin S.H., Welsh J.W., O'Reilly M.S., et al. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 2013, 52(5):1002-1009. Epub 2012/09/07.
67. Skinner H.D., Sandulache V.C., Ow T.J., Meyn R.E., Yordy J.S., Beadle B.M., et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2012, 18(1):290-300. Epub 2011/11/18.
68. Zannella VE, Pra AD, Muaddi H, McKee TD, Stapleton S, Sykes J, et al. Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013. Epub 2013/10/22.
69. Frasca F., Pandini G., Sciacca L., Pezzino V., Squatrito S., Belfiore A., et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008, 114(1):23-37. Epub 2008/05/10.
70. Dowling R.J., Zakikhani M., Fantus I.G., Pollak M., Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007, 67(22):10804-10812. Epub 2007/11/17.
71. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Engl J Med 2012, 366(10):883-892. Epub 2012/03/09.
72. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New Engl J Med 2005, 353(16):1659-1672. Epub 2005/10/21.
73. Turner N.C., Reis-Filho J.S. Genetic heterogeneity and cancer drug resistance. Lancet Oncol 2012, 13(4):e178-e185. Epub 2012/04/04.
74. Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. New Engl J Med 2012, 366(10):925-931. Epub 2012/03/09.
75. Lee Y., Auh S.L., Wang Y., Burnette B., Wang Y., Meng Y., et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009, 114(3):589-595. Epub 2009/04/08.
76. Grosso J.F., Jure-Kunkel M.N. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013, 13:5. Epub 2013/02/08.
77. Pilones K.A., Vanpouille-Box C., Demaria S. Combination of radiotherapy and immune checkpoint inhibitors. Semin Radiat Oncol 2015, 25(1):28-33.
78. Demaria S., Pilones K.A., Formenti S.C., Dustin M.L. Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. Oncoimmunology 2013, 2(3):e23127. Epub 2013/06/27.
79. Dewan M.Z., Galloway A.E., Kawashima N., Dewyngaert J.K., Babb J.S., Formenti S.C., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009, 15(17):5379-5388. Epub 2009/08/27.
80. PD-1 Inhibitor Approved for Melanoma. Cancer discovery. 2014;4(11):1249. Epub 2014/11/05.
81. Zeng J., See A.P., Phallen J., Jackson C.M., Belcaid Z., Ruzevick J., et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013, 86(2):343-349. Epub 2013/03/07.
82. Harrington K.J., Billingham L.J., Brunner T.B., Burnet N.G., Chan C.S., Hoskin P., et al. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer 2011, 105(5):628-639.